Dapagliflozin for active lupus kidney disease
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This study tests if a diabetes drug called dapagliflozin can help people with active lupus nephritis by reducing protein in the urine and preserving kidney function. It is given in addition to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with lupus and have a kidney biopsy showing lupus nephritis (class III, IV, or V).
- Your lupus kidney disease is active (new or flaring) within the last 6 months.
- You are on standard medications for lupus nephritis, such as mycophenolate, cyclophosphamide, belimumab, or others.
- You have taken steroids for lupus kidney disease in the past 6 months and are on an antimalarial drug and/or blood pressure medication for kidney protection.
- You have significant protein or microalbumin in your urine (at least 0.5 grams per gram of creatinine).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if empagliflozin, a medicine used for diabetes, can help protect kidney function in people with active lupus nephritis. You may be eligible if you have a lupus kidney flare with significant protein in your urine.
This trial tests if a type of diabetes medicine (SGLT-2 inhibitors) can reduce protein in the urine and protect kidney function in people with chronic kidney disease caused by lupus nephritis or ANCA-associated vasculitis. The medicine is already approved for other conditions, and researchers want to see if it works for these kidney diseases.
This study tests whether a medicine called an SGLT2 inhibitor (which lowers blood sugar and helps the kidneys) can improve outcomes for people with acute heart failure and kidney problems. Participation involves taking the study drug or a placebo for a short time.
This study tests whether the medicine empagliflozin is safe and helpful for adults who are on regular hemodialysis and still make a small amount of urine. The goal is to see if it can improve health outcomes while tracking side effects closely.
This study tests if an SGLT2 inhibitor can help protect kidney function in people who have lupus nephritis (kidney inflammation caused by lupus) and chronic kidney disease (CKD). The goal is to see if this medicine can slow down further kidney damage.
This trial tests whether a diabetes drug called dapagliflozin can help people on peritoneal dialysis keep their remaining kidney function longer. It is for patients who started dialysis recently and still make urine.
Hear when a new Lupus Nephritis (LN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.